Survodutide

What is Survodutide?#

Survodutide (development code BI 456906) is a novel dual agonist peptide that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is being developed by Boehringer Ingelheim and Zealand Pharma and is currently in Phase 3 clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). Survodutide represents a pharmacological approach that combines the appetite-suppressing and glucose-lowering effects of GLP-1 receptor agonism with the energy expenditure-enhancing and lipid-mobilizing effects of glucagon receptor agonism.

The dual agonist concept for survodutide emerged from the recognition that while GLP-1 receptor agonists (such as semaglutide and liraglutide) achieve weight loss primarily through appetite reduction and slowed gastric emptying, they do not substantially increase energy expenditure. Glucagon, traditionally viewed as a counter-regulatory hormone opposing insulin's metabolic effects, has potent thermogenic and lipolytic properties that can complement GLP-1-mediated caloric reduction. However, glucagon receptor agonism alone would be expected to raise blood glucose levels through hepatic glycogenolysis and gluconeogenesis. By combining both receptor activities in a single molecule, survodutide aims to achieve synergistic weight loss and metabolic improvement while using the glucose-lowering effect of GLP-1R activation to offset the hyperglycemic potential of glucagon signaling.

Survodutide is designed as a peptide-based molecule with relative activity ratios favoring glucagon receptor activation approximately 4-5 fold over GLP-1 receptor activation. This glucagon-favoring ratio distinguishes it from other dual and triple agonists in development, such as tirzepatide (GIP/GLP-1 dual agonist) and retatrutide (GIP/GLP-1/glucagon triple agonist), which employ different receptor combinations and activity ratios. The molecule has been engineered for once-weekly subcutaneous administration through structural modifications that extend its pharmacokinetic half-life.

Mechanism of Action#

GLP-1 Receptor Agonism#

The GLP-1 receptor component of survodutide's mechanism operates through well-characterized pathways shared with approved GLP-1 receptor agonists. Upon binding to GLP-1R, a class B G-protein coupled receptor expressed on pancreatic beta cells, neurons in the hypothalamus and brainstem, and gastrointestinal tract cells, survodutide activates Gs-alpha signaling and downstream cAMP-dependent pathways.

In the central nervous system, GLP-1R activation in the arcuate nucleus, paraventricular nucleus, and nucleus of the solitary tract modulates appetite-regulating circuits, suppressing hunger and promoting satiety. These effects are mediated through inhibition of orexigenic (appetite-stimulating) NPY/AgRP neurons and activation of anorexigenic POMC/CART neurons. GLP-1R activation also slows gastric emptying via vagal afferent signaling, contributing to reduced caloric intake per meal.

In the pancreas, GLP-1R activation on beta cells enhances glucose-dependent insulin secretion through the cAMP/PKA and Epac2 pathways, improving glycemic control. Critically, this insulinotropic effect is glucose-dependent, meaning it occurs primarily during hyperglycemia and diminishes as blood glucose normalizes, providing intrinsic protection against hypoglycemia.

Glucagon Receptor Agonism#

The glucagon receptor component distinguishes survodutide from pure GLP-1 receptor agonists and is central to its differentiated metabolic profile. Glucagon binds to the glucagon receptor (GCGR), another class B GPCR expressed predominantly in the liver, but also in adipose tissue, kidney, heart, and brain. GCGR activation initiates Gs-coupled cAMP signaling, which in hepatocytes activates PKA and downstream phosphorylation cascades.

The metabolic consequences of GCGR activation relevant to survodutide's therapeutic effects include several key pathways.

First, hepatic energy expenditure and thermogenesis are increased. Glucagon stimulates hepatic mitochondrial oxidative phosphorylation and futile cycling, increasing basal metabolic rate. This thermogenic effect has been demonstrated in human studies where glucagon infusion increased resting energy expenditure by 100-200 kcal/day. In the context of survodutide, this increased energy expenditure provides an additive mechanism of weight loss beyond the appetite suppression achieved through GLP-1R activation.

Second, glucagon promotes lipolysis in both hepatic and adipose tissue. In the liver, GCGR activation stimulates fatty acid beta-oxidation and ketogenesis while reducing hepatic de novo lipogenesis and VLDL secretion. This hepatic lipid mobilization is of particular relevance to MASH, where hepatic steatosis (fat accumulation) is a central pathological feature.

Third, glucagon stimulates hepatic glycogenolysis and gluconeogenesis, raising blood glucose levels. This is the primary concern with glucagon receptor agonism that necessitates the counterbalancing GLP-1R activity in survodutide's dual mechanism.

Synergistic Dual Mechanism#

The therapeutic rationale for survodutide rests on the synergistic and complementary interaction between its two receptor activities. The GLP-1R component suppresses appetite, slows gastric emptying, and lowers blood glucose. The GCGR component increases energy expenditure, promotes hepatic fat oxidation, and mobilizes lipid stores. The glucose-lowering effect of GLP-1R activation offsets the hyperglycemic tendency of GCGR activation, while the combined caloric reduction (GLP-1) and increased expenditure (glucagon) produce greater net negative energy balance than either mechanism alone.

Preclinical studies in diet-induced obese mice demonstrated that the dual GLP-1/glucagon agonist approach produced greater weight loss than equipotent doses of either receptor agonist alone, with preservation of lean body mass and preferential loss of fat mass. These findings were attributed to the glucagon-driven increase in energy expenditure, which is not observed with GLP-1 agonist monotherapy.

Therapeutic Applications and Clinical Evidence#

Phase 2 COURAGE Trial (Obesity)#

The COURAGE trial was a Phase 2, randomized, double-blind, placebo-controlled, dose-finding study evaluating survodutide in adults with overweight or obesity (BMI 28 or greater) without diabetes. The trial enrolled 387 participants randomized to one of four survodutide dose groups (0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg once weekly, with dose escalation) or placebo for 46 weeks.

Results demonstrated dose-dependent weight loss across all survodutide groups. At the highest dose (4.8 mg), participants achieved a mean body weight reduction of 14.9% from baseline at week 46, compared to 2.8% with placebo (treatment difference -12.1 percentage points, p<0.001). The 3.6 mg dose group achieved approximately 13.2% weight loss, and the 2.4 mg group achieved approximately 10.9%. At 46 weeks, 83% of participants in the 4.8 mg group achieved at least 5% body weight loss, and 57% achieved at least 15% loss.

Extended data from a 16-week treatment-free follow-up showed partial weight regain after discontinuation, consistent with findings from other incretin-based therapies and supporting the likely need for chronic treatment to maintain weight loss.

Improvements in cardiometabolic risk factors accompanied the weight loss, including reductions in waist circumference, improvements in lipid profiles (triglycerides, non-HDL cholesterol), and reductions in markers of systemic inflammation (high-sensitivity C-reactive protein). Blood glucose and HbA1c levels remained stable or improved across dose groups, confirming that the GLP-1R component adequately counterbalanced the glucagon-mediated hyperglycemic tendency.

Phase 2b MASH Trial#

The efficacy of survodutide in MASH was evaluated in a Phase 2b, randomized, double-blind, placebo-controlled trial enrolling 293 patients with biopsy-confirmed MASH and liver fibrosis stages F1-F3. Participants were randomized to survodutide (2.4 mg, 4.8 mg, or 6.0 mg weekly, with dose escalation) or placebo for 48 weeks.

At 48 weeks, histological improvement was observed in a significantly greater proportion of survodutide-treated patients compared to placebo. In the 4.8 mg group, 47% of patients achieved MASH resolution without worsening of fibrosis, compared to 14% with placebo (p<0.001). Improvement in liver fibrosis by at least one stage was observed in 36% of the 4.8 mg group versus 22% with placebo.

Survodutide also produced substantial reductions in liver fat content as measured by MRI-based proton density fat fraction (PDFF). The 4.8 mg dose group showed a mean relative reduction in liver fat of approximately 64% from baseline, compared to 6% with placebo. Serum alanine aminotransferase (ALT) levels, a marker of hepatocellular injury, improved significantly across all survodutide dose groups.

These MASH findings are considered particularly notable because they suggest that the glucagon receptor component provides direct hepatic benefits beyond weight loss alone, consistent with the known role of glucagon in promoting hepatic lipid oxidation and reducing steatosis.

Phase 3 Program#

Based on the Phase 2 results, Boehringer Ingelheim initiated a comprehensive Phase 3 clinical program for survodutide. The ACHIEVE Phase 3 program includes trials in both obesity (ACHIEVE-1, evaluating weight loss in adults without diabetes) and MASH (multiple trials evaluating histological endpoints). The Phase 3 trials are evaluating survodutide doses up to 6.0 mg weekly with optimized titration schedules designed to improve gastrointestinal tolerability.

Safety and Tolerability Profile#

The safety profile of survodutide in clinical trials to date has been generally consistent with the class effects of incretin-based therapies. The most commonly reported adverse events are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These events were predominantly mild to moderate in severity, occurred most frequently during dose escalation periods, and tended to diminish with continued treatment.

In the COURAGE trial, treatment discontinuation due to adverse events occurred in approximately 10-15% of patients in the higher-dose groups, compared to 4% with placebo. Nausea was the most common reason for discontinuation. The gastrointestinal tolerability profile has informed the design of Phase 3 trials, which employ more gradual dose escalation schedules.

Heart rate increases of 2-6 beats per minute were observed with survodutide, consistent with effects seen across the incretin-based therapy class. Cases of transient, asymptomatic increases in lipase and amylase were reported, though no confirmed cases of pancreatitis occurred in Phase 2 trials.

Comparison with Other Incretin Therapies#

Survodutide occupies a unique position in the evolving landscape of incretin-based and multi-receptor agonist therapies for obesity and metabolic disease. While direct comparison across trials is methodologically limited, the Phase 2 weight loss of approximately 15% at 46 weeks positions survodutide competitively relative to other agents in development.

Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 receptor agonist, demonstrated weight loss of up to 22.5% at 72 weeks in the SURMOUNT-1 trial. However, tirzepatide lacks glucagon receptor activity and its effects are mediated through the GIP/GLP-1 combination rather than the glucagon/GLP-1 approach of survodutide. Retatrutide, a triple GIP/GLP-1/glucagon agonist also incorporating glucagon activity, showed weight loss of up to 24% at 48 weeks in Phase 2.

The differentiation of survodutide may ultimately rest on its MASH efficacy, where the hepatic benefits of glucagon signaling provide a mechanistic advantage that GIP/GLP-1 dual agonists may not fully replicate. The MASH indication represents a large unmet medical need with limited approved therapies, and survodutide's dual mechanism is well-suited to address the hepatic lipid accumulation central to MASH pathology.

Evidence Gaps and Limitations#

Phase 3 Data Pending#

The clinical evidence for survodutide is currently based on Phase 2 trials, which are designed for dose-finding and signal detection rather than definitive efficacy determination. The ongoing Phase 3 ACHIEVE program will provide the pivotal data needed for regulatory submissions and more definitive characterization of the benefit-risk profile. Until Phase 3 results are available, conclusions about survodutide's efficacy and safety should be interpreted with the limitations of Phase 2 data in mind.

Long-Term Safety#

Long-term safety data for survodutide extending beyond 48-52 weeks is not yet available. As a novel dual agonist with significant glucagon receptor activity, there are theoretical concerns regarding long-term effects on hepatic glucose output, potential for lean body mass loss, effects on bone metabolism, and cardiovascular outcomes. The Phase 3 program is expected to include longer treatment durations and dedicated cardiovascular outcomes studies to address these questions.

Glucagon-Specific Risks#

The glucagon receptor agonism in survodutide introduces pharmacological effects not present in approved GLP-1 receptor agonists. While the glucose-elevating tendency of glucagon signaling was adequately managed in Phase 2 trials, the long-term effects of chronic glucagon receptor stimulation on hepatic function, pancreatic alpha-cell dynamics, and ketone body production have not been fully characterized. Additionally, the optimal ratio of glucagon-to-GLP-1 activity for maximizing efficacy while minimizing adverse effects has not been definitively established.

Patient Population Breadth#

Phase 2 trials enrolled relatively selected patient populations. The efficacy and safety of survodutide in broader populations, including patients with type 2 diabetes, those with more severe obesity (BMI above 50), elderly patients, and individuals with significant renal or hepatic impairment, remain to be established through the Phase 3 program and post-marketing studies.

Structural and Sequence Data#

The full amino acid sequence and detailed structural characterization of survodutide have not been publicly disclosed in peer-reviewed literature. The molecule is described as a modified peptide-based dual agonist, but the specific structural modifications conferring its receptor activity profile, half-life extension, and stability remain proprietary. This limits independent analysis of its structure-activity relationships and comparison with other molecules in the class.

Comparative Effectiveness#

No head-to-head clinical trials comparing survodutide with approved GLP-1 receptor agonists (semaglutide, liraglutide), tirzepatide, or other agents in development have been conducted. Cross-trial comparisons are inherently limited by differences in patient populations, trial designs, dose escalation schedules, treatment durations, and endpoint definitions. Direct comparative trials will be necessary to establish the relative clinical positioning of survodutide.

Weight Regain#

Consistent with other incretin-based therapies, preliminary data from the treatment-free follow-up period of the COURAGE trial suggests weight regain after discontinuation. This raises questions about the need for chronic treatment, the long-term cost-effectiveness of indefinite therapy, and whether strategies to maintain weight loss after discontinuation can be developed.

Key Research Findings#

Efficacy and Safety of Survodutide (BI 456906), a Dual Glucagon Receptor/GLP-1 Receptor Agonist, in Adults with Overweight or Obesity: A Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Trial (COURAGE), published in The Lancet (Blueher M et al., 2024):

• The study showed dose dependent weight loss of 0.6 mg , 2.4 mg , 3.6 mg , 4.8 mg vs placebo at 46 weeks

Survodutide for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis: A Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial, published in The Lancet (Sanyal AJ et al., 2024):

• The study showed MASH resolution without worsening fibrosis of 47% vs 14% , p<0.001
• The study showed fibrosis improvement by at least one stage of 36% vs 22%
• The study showed mean relative liver fat reduction by MRI PDFF of 64% vs 6%

Related Reading#

• Survodutide research studies and evidence
• Survodutide dosing protocols
• Survodutide side effects profile
• Amycretin research guide
• Mazdutide research guide